Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Former Benesis GMP Violation: Ueda Vows to “Root Out” Problems in JBPO
October 19, 2012
- JBPO Looks to Boost Japan’s Self-Sufficiency Ratio of Plasma Derivatives, Mulls Further Integration: Pres. Ueda
October 18, 2012
- Mr Kaiya of Kyokai Kenpo Optimistic About Reaching 30% Generic Drug Use Target
October 18, 2012
- Sino-Japanese Pharmaceutical Exchange Symposium to Be Postponed at Request of China: OPMA
October 15, 2012
- OPMA Temporarily Freezes JBPO’s Appointment as Its Board Member, FPMAJ’s Member of Board of Trustees
October 15, 2012
- Permanent New Drug Premium, Expanded R&D Tax Credits Needed to Encourage Innovation and Investment: FPMAJ Chairman Naito
October 12, 2012
- Price Gap between Long-Listed Products, Generics Necessary: FPMAJ Chairman Naito
October 11, 2012
- President Teshirogi of JPMA Stresses Need for Asian Countries to Cooperate in Drug Discovery
October 11, 2012
- Proposal to Unify Basic Dispensing Fees Could Be Taken Up Again: JPA Vice President Miura
October 10, 2012
- Life Science Budget in Japan Lacks Absolute Amount: JPMA President Teshirogi
October 10, 2012
- “Industry Also Needs to Consider” Distribution of Drug Expenditure: Former Administrative Vice Minister of Health Erikawa
October 5, 2012
- Enterprise Integration Has Not Yet Advanced among Drugmakers in Japan: Former JFTC Chairman Takeshima
September 27, 2012
- MHLW to Announce 14 New Examples of Approved Off-Label Drug Use Based on 1980 Notification in Near Future
September 26, 2012
- Risk for 7 Main Diseases Increases at Age 63: Anti-Aging Laboratory
September 25, 2012
- JPA Issues Notice on Prohibition of Dispensing Point Services, “Not Intended as Transitional Measure”
September 25, 2012
- Wholesale Industry FTC’s Liaison Conference on Ending Provision of Free Benefits and Labor to Hold 1st Meeting in October
September 25, 2012
- MHLW Reports Results of Analysis of “Close-Call” Incidents at Pharmacies with Generics
September 24, 2012
- Mr Hayashi of OPIR Stresses Need for Approval and Reimbursement of More Companion Diagnostics
September 21, 2012
- Dr Fukuda Lays Out 4 Options for HTA Introduction in Drug Pricing
September 20, 2012
- Anti-Japanese Demonstrations in China Have Had “Absolutely No Effect” on Takeda: President Hasegawa
September 20, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…